Login to Your Account

Re-branded Inspyr secures up to $100M as mipsagargin rounds bend

By Marie Powers
News Editor

Monday, March 20, 2017

With multiple phase II studies of lead compound, mipsagargin (G-202), under its belt, Inspyr Therapeutics Inc. (formerly Genspera Inc.) inked an agreement with private equity firm Milost Global Inc. for up to $100 million to fund the next stage of development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription